IL1B and systemic lupus erythematosus: Finally, severe complications occurring in lupus patients, such as macrophage activation syndrome or pericarditis, have been successfully reduced with anakinra, an IL-1b antagonist [30,31], showing that both IFNs-I and IL-1 participate in lupus pathogenesis, at least in a subset of patients.